USPIO MRI in protate cancer: Vascular imaging and lymph node staging
- Prosjektnummer
- 90059700
- Ansvarlig person
- Jana Kim
- Institusjon
- NTNU, ISB
- Prosjektkategori
- Postdoc-stipend 2016
- Helsekategori
- Cancer
- Forskningsaktivitet
- 4. Detection and Diagnosis, 6. Treatment Evaluation
In the last year we have finalized a publication concerning the optimization of dynamic contrast-enhanced (DCE) MRI acquisition and analysis for cancer detection and treatment response assessment. The main conclusion of this paper is that DCE-MRI based biomarkers can underestimate treatment response in cancer at high magnetic field strengths. Both preclinical and clinical MRI are moving towards higher magnetic fields, which makes these results highly relevant for future clinical studies. The paper will be submitted within the next month. Another side project has been completed last year, which concerned the characterization imaging biomarkers for assessment of targeted nanoparticle therapy in of mouse models of cancer, including prostate cancer. One paper has been published for this project. We have also initiated preclinical studies with another research group examining the use of high intensity focused ultrasound for the treatment of prostate cancer. My involvement in their research is significant and will continue past the end of my Postdoctoral contract. We expect to write two publications from this work.
Multi-modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft models.
J Control Release 2018 Jun 10;279():292-305. Epub 2018 apr 21
PMID: 29684498
Multiparametric characterization of response to anti-angiogenic therapy using USPIO contrast-enhanced MRI in combination with dynamic contrast-enhanced MRI.
J Magn Reson Imaging 2017 Dec 04. Epub 2017 des 4
PMID: 29205621
- Tone Frost Bathen Forskningsgruppeleder
- Siver Andreas Moestue Prosjektleder
- Jana Cebulla Postdoktorstipendiat
- Eugene Kim Forsker
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Helse Midt-Norge RHF - Samarbeidsorganet og FFU